Cocrystal Pharma, Inc.

Contributing Author

Recent Articles by Cocrystal Pharma, Inc.

Jun-03	Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer COCP GlobeNewswire
May-26	Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza COCP GlobeNewswire
May-15	Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results COCP GlobeNewswire
Apr-30	Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection COCP GlobeNewswire
Apr-02	Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive COCP +48.04% GlobeNewswire
Mar-31	Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs COCP GlobeNewswire
Mar-09	First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment COCP GlobeNewswire
Feb-19	Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 COCP GlobeNewswire
Dec-18	Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus COCP GlobeNewswire
Dec-01	Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference COCP GlobeNewswire
Nov-14	Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs COCP GlobeNewswire
Oct-30	Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules COCP GlobeNewswire
Oct-27	Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program COCP GlobeNewswire
Oct-02	Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference COCP GlobeNewswire
Sep-15	Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules COCP -9.49% COCP -7.69% GlobeNewswire
Sep-12	Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules COCP +9.72% GlobeNewswire
Sep-12	Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference COCP +9.72% GlobeNewswire
Sep-08	Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment COCP GlobeNewswire
Sep-03	Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference COCP GlobeNewswire
Aug-14	Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs COCP GlobeNewswire
Aug-05	Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference COCP -14.95% GlobeNewswire
Jul-10	Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference COCP GlobeNewswire
Jun-05	Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference COCP GlobeNewswire
May-29	Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain COCP +8.74% GlobeNewswire
May-28	Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference COCP GlobeNewswire
May-15	Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs COCP GlobeNewswire

Cocrystal Pharma, Inc.

Recent Articles by Cocrystal Pharma, Inc.

Upgrade your Finviz experience